Every vendor deck in clinical research has “AI-powered” somewhere on slide two. Every conference agenda has an AI panel. And yet, a landmark State of Clinical AI report published by Stanford and Harvard in January 2026 drew a conclusion that should give every biometrics leader pause: many claims of “physician-level” or “superhuman” AI performance rely on narrow benchmarks that don’t survive contact with real-world trial complexity. The gap between what AI promises in a controlled demo and what it delivers on a live study is where most of the industry’s AI budget quietly disappears.
That doesn’t make AI useless. It makes honest evaluation essential.
Where AI Is Genuinely Earning Its Place
In clinical data management, AI’s strongest ROI today is narrow, specific, and measurable — and that’s precisely its strength. Machine learning models applied to anomaly detection are identifying outliers, protocol deviations, and unusual data entry patterns that rule-based edit checks routinely miss. Platforms like CluePoints and Medidata Detect use statistical algorithms combined with ML to flag site-level risks in near real-time — a capability that manual review simply cannot match at scale when Phase III trials now generate an average of 3.6 million data points per patient.
AI-driven risk-based monitoring is another area of genuine value. Rather than applying the same visit schedule to every site, AI models adapt continuously — focusing oversight where the data actually signals risk. Industry benchmarks from ICH E6(R3) implementation show remote monitoring approaches, enabled by centralised analytics, are already delivering around 30% reductions in travel costs without compromising data fidelity. That’s not hype. That’s a measurable operational win.
Patient recruitment is the third area where the numbers hold up. AI-assisted site selection and patient matching have shown 65% faster enrolment and 50% reduction in screening failures in documented implementations. Given that 80% of trials experience significant delays due to enrolment challenges, and 37% of sites fail to recruit a single participant, this matters enormously to sponsors and CROs alike.
Where AI Is Still More Promise Than Practice
The honest assessment is harder to find in vendor literature, but it’s critical to understand. The Stanford-Harvard report is unambiguous: AI models that perform impressively on fixed clinical cases frequently underperform when deployed against heterogeneous, real-world populations. Training data bias is a persistent problem — models built on data from well-resourced institutions generalise poorly to diverse global trial settings.
For biometrics teams specifically, the “black box” problem has direct regulatory consequences. The FDA and EMA are not accepting AI-supported clinical decisions without traceable, explainable logic and documented data provenance. The EU AI Act is adding further compliance requirements. Any organisation deploying AI for endpoint derivation, safety signal review, or eligibility determination without human-in-the-loop oversight and full audit trail documentation is building a regulatory liability, not an efficiency gain.
In drug discovery, the frustration is even sharper. Multiple AI-designed drug candidates were deprioritised or shelved after Phase II in 2025, and one CEO’s assessment — that AI has “really let us all down” in drug discovery over the past decade — reflects industry frustration that is real, even if it overstates the case. The truth is that no AI-discovered drug has yet achieved full regulatory approval. Until that changes, the entire field is still in proof-of-concept territory.
The Three Questions Every Biometrics Team Should Ask
Before committing to any AI tool in a clinical programme, three questions cut through the noise.
Is this AI, or is this automation?
Much of what vendors market as “AI” is rule-based automation with a modern interface. Automation is valuable — it reduces manual burden and human error. But it is not the same as machine learning applied to novel pattern recognition. Knowing which you’re actually buying changes the evaluation criteria entirely.
Can it explain its outputs to a regulator?
If the answer is “not without significant documentation effort,” the tool is not ready for deployment in submission-critical workflows. Explainability is not optional under current FDA and EMA guidance — it is a prerequisite for any AI touching primary endpoints or safety data.
What’s the validation pathway?
AI systems in clinical trials require the same rigorous validation as any other computerised system under 21 CFR Part 11 and ICH E6(R3). Model versions need to be captured. Training data needs to be documented. Governance needs to be written into the DMP. If a vendor cannot clearly describe their validation framework, the tool is not production-ready.
“AI should narrow the search space for human experts — not eliminate the expert.”
The Right Frame: Augmentation, Not Replacement
The biometrics professionals who will gain the most from AI are those who treat it as a precision instrument for the tasks where it genuinely excels: surfacing anomalies in large datasets, flagging sites at risk before they become problems, and accelerating query resolution workflows. The professionals who will struggle are those waiting for AI to make the hard judgments — on safety signals, on endpoint validity, on the clinical meaning of an unexpected data pattern — that still require therapeutic area knowledge, regulatory understanding, and professional accountability.
The industry consensus heading into 2026, from Applied Clinical Trials to Clinical Trials Arena, is consistent: AI is a powerful tool in the hands of domain-expert teams, and a liability in the hands of teams that treat it as a shortcut. The organisations seeing measurable returns are those that started narrow — one workflow, one measurable outcome, one validated tool — and expanded from there. The ones that over-invested in broad AI transformation programmes without that foundational discipline are quietly walking those programmes back. For biometrics specifically, the message is clear: deep clinical knowledge and regulatory accountability remain the non-negotiable core. AI sharpens the edge. It does not replace it.
Final Thoughts
The practical implication for any sponsor or CRO evaluating AI in their biometrics function is this: start with the problem, not the technology. Identify where your highest-friction points are — query backlog, site performance variance, data reconciliation bottlenecks — and evaluate AI tools against those specific needs with defined success metrics. Run pilots. Measure time saved, errors reduced, and user adoption. Then scale what works.
Zuality’s Technology Solutions practice helps sponsors and CROs do exactly this — evaluating, implementing, and validating the right tools for each programme, without the vendor hype and with full regulatory accountability built in from day one.
